About Us
We work with humility, tenacity, and perseverance as we strive to provide patients with hope that better options are on the horizon.
Neurocrine has a heritage based in science and collaboration that remains the hallmark of our culture today.
From two people to a company of more than 1,200, our
purpose and values
remain rooted in the needs of underserved patients worldwide.
Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning Stanford University neurologist Lawrence Steinman, Ph.D. Since then, we have been developing treatments for rare and under-addressed diseases, sometimes in collaboration with other pharmaceutical companies.
The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline including multiple compounds in mid-to-late phase clinical development across our core therapeutic areas.
Neurocrine co-founder, Wylie Vale, Ph.D.
Neurocrine co-founder, Lawrence Steinman, Ph.D.
Meeting the needs of underserved patients remains our purpose today and as we move into the future.
Our
Dedication
to Scientific Discovery
Our foundational work began in neuroendocrine disorders with our co-founder Dr. Vale’s discovery and study of corticotropin-releasing factor (CRF), an important stress hormone that regulates the release of adrenocorticotropic hormone (ACTH) from the pituitary gland. This work led to the understanding of key biological pathways involved in congenital adrenal hyperplasia (CAH), a rare, genetic, life-long and life-threatening disorder caused by an enzyme deficiency. Mentored by Dr. Vale, Dimitri E. Grigoriadis, Ph.D., first served as our Director of Pharmacology and Drug Discovery and led the development efforts of several CRF receptor antagonists for neuropsychiatric and neuroendocrine disorders. One of the compounds was crinecerfont for CAH, an investigational CRF1 receptor antagonist that could bring innovation to a patient community that has not seen advancements in care in more than 70 years.
A passion for fulfilling unmet needs has guided our research efforts and ongoing perseverance throughout our history. Vesicular monoamine transporter 2 (VMAT2), a protein in the brain that packages neurotransmitters, such as dopamine, was identified in the 1990s. Less than a decade later, an understanding of the critical role of the VMAT2 pathway in regulating movement led scientists at Neurocrine to synthesize valbenazine, a VMAT2 inhibitor, with the aim of reducing the amount of dopamine released in the striatum. In 2017, after years of research and clinical trials, valbenazine was approved by the FDA for a first indication and for a second indication in 2023. We continue to study valbenazine in additional patient populations, including for certain neurological and neuropsychiatric conditions.
Our
Purpose
is to relieve suffering for people
with great needs, but few options.
Passion
We are driven and love what we do. We are committed to our goals and to making a difference.
Integrity
We do the right thing for patients and our community. We take accountability. We speak up.
Collaboration
We trust one another. We are inclusive. We are respectful. We are transparent. Together we succeed.
Innovation
We seek and create optimal solutions.
Tenacity
We do not quit. We adapt. We accomplish what others cannot.
Hear more about Neurocrine from those who know us best—our employees
Our
Responsibility
Our
Leadership
